$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000153217616000055 Filed on May 05, 2016

Income Statement

Concept	2016 Q1	2015 Q1
Revenue	$1.201B	$869.6M
YoY Change	38.09%	38.97%
Cost Of Revenue	$78.94M	$42.57M
YoY Change	85.44%	54.95%
Gross Profit	$1.122B	$827.0M
YoY Change	35.65%	38.24%
Gross Profit Margin	93.43%	95.1%
Selling, General & Admin	$289.7M	$159.0M
YoY Change	82.2%	54.02%
% of Gross Profit	25.82%	19.22%
Research & Development	$470.1M	$343.1M
YoY Change	37.01%	19.39%
% of Gross Profit	41.9%	41.49%
Depreciation & Amortization	$22.98M	$16.03M
YoY Change	43.36%	39.0%
% of Gross Profit	2.05%	1.94%
Operating Expenses	$759.8M	$502.1M
YoY Change	51.32%	28.54%
Operating Profit	$329.3M	$283.6M
YoY Change	16.14%	48.02%
Interest Expense	-$2.640M	$6.169M
YoY Change	-142.79%	-46.88%
% of Operating Profit	-0.8%	2.18%
Other Income/Expense, Net	$843.0K	-$7.030M
YoY Change	-111.99%	-34.15%
Pretax Income	$330.2M	$276.5M
YoY Change	19.39%	52.87%
Income Tax	$148.8M	$200.5M
% Of Pretax Income	45.06%	72.51%
Net Earnings	$181.4M	$76.02M
YoY Change	138.6%	11.3%
Net Earnings / Revenue	15.1%	8.74%
Basic Earnings Per Share	$1.74	$0.74
Diluted Earnings Per Share	$1.59	$0.66
COMMON SHARES
Basic Shares Outstanding	104.3M shares	102.2M shares
Diluted Shares Outstanding	114.2M shares	114.5M shares

Balance Sheet

Concept	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$849.0M	$742.0M
YoY Change	14.42%	14.51%
Cash & Equivalents	$604.2M	$507.9M
Short-Term Investments	$245.0M	$234.0M
Other Short-Term Assets	$162.0M	$125.0M
YoY Change	29.6%	16.82%
Inventory	$303.3M	$133.9M
Prepaid Expenses
Receivables	$1.451B	$1.016B
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$3.133B	$2.311B
YoY Change	35.6%	23.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.666B	$1.111B
YoY Change	50.04%	84.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$555.0M	$483.0M
YoY Change	14.91%	-9.72%
Other Assets	$5.791M	$4.473M
YoY Change	29.47%	-16.24%
Total Long-Term Assets	$2.771B	$1.888B
YoY Change	46.78%	35.88%
TOTAL ASSETS
Total Short-Term Assets	$3.133B	$2.311B
Total Long-Term Assets	$2.771B	$1.888B
Total Assets	$5.904B	$4.199B
YoY Change	40.63%	28.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$121.0M	$91.00M
YoY Change	32.97%	175.76%
Accrued Expenses	$469.0M	$372.0M
YoY Change	26.08%	81.46%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$919.7M	$536.1M
YoY Change	71.55%	75.74%
LONG-TERM LIABILITIES
Long-Term Debt	$362.0M	$472.0M
YoY Change	-23.31%	-10.94%
Other Long-Term Liabilities	$121.0M	$55.56M
YoY Change	117.77%	371.08%
Total Long-Term Liabilities	$121.0M	$55.56M
YoY Change	117.77%	371.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$919.7M	$536.1M
Total Long-Term Liabilities	$121.0M	$55.56M
Total Liabilities	$2.139B	$1.227B
YoY Change	74.34%	16.97%
SHAREHOLDERS EQUITY
Retained Earnings	$1.018B	$292.7M
YoY Change	247.99%	-1174.04%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$307.5M	$181.8M
YoY Change	69.11%
Treasury Stock Shares	3.660M shares	2.164M shares
Shareholders Equity	$3.765B	$2.971B
YoY Change
Total Liabilities & Shareholders Equity	$5.904B	$4.199B
YoY Change	40.63%	28.77%

Cashflow Statement

Concept	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	$181.4M	$76.02M
YoY Change	138.6%	11.3%
Depreciation, Depletion And Amortization	$22.98M	$16.03M
YoY Change	43.36%	39.0%
Cash From Operating Activities	$44.99M	-$101.7M
YoY Change	-144.23%	-290.05%
INVESTING ACTIVITIES
Capital Expenditures	-$104.1M	-$114.2M
YoY Change	-8.84%	76.23%
Acquisitions
YoY Change
Other Investing Activities	$60.40M	-$15.30M
YoY Change	-494.77%	-91.07%
Cash From Investing Activities	-$43.69M	-$129.5M
YoY Change	-66.26%	-45.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$39.30M	$76.27M
YoY Change	-48.47%	38.57%
Debt Paid & Issued, Net	$598.0K
YoY Change
Cash From Financing Activities	-$206.2M	$90.40M
YoY Change	-328.1%	-17.03%
NET CHANGE
Cash From Operating Activities	$44.99M	-$101.7M
Cash From Investing Activities	-$43.69M	-$129.5M
Cash From Financing Activities	-$206.2M	$90.40M
Net Change In Cash	-$204.9M	-$140.8M
YoY Change	45.5%	90.93%
FREE CASH FLOW
Cash From Operating Activities	$44.99M	-$101.7M
Capital Expenditures	-$104.1M	-$114.2M
Free Cash Flow	$149.1M	$12.47M
YoY Change	1095.29%	-89.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC
CY2014Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	56200000	USD
CY2015Q1	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	84100000	USD
CY2015Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	50700000	USD
CY2016Q1	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	44600000	USD
CY2015Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	88297000	USD
CY2016Q1	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	82533000	USD
CY2015Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	195986000	USD
CY2016Q1	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	190763000	USD
CY2015Q1	regn	Costofmanufacturing Costofmanufacturing	41385000	USD
CY2016Q1	regn	Costofmanufacturing Costofmanufacturing	32810000	USD
CY2016Q1	regn	Debt Conversion DebtConversion	1700000	USD
CY2015Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	101573000	USD
CY2016Q1	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	99314000	USD
CY2015Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	582664000	USD
CY2016Q1	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	565773000	USD
CY2015Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	362919000	USD
CY2016Q1	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	362230000	USD
CY2015Q1	regn	Facilityleaseobligationrecognizedduringtheperiod Facilityleaseobligationrecognizedduringtheperiod	10800000	USD
CY2016Q1	regn	Facilityleaseobligationrecognizedduringtheperiod Facilityleaseobligationrecognizedduringtheperiod	0	USD
CY2015Q1	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	467000	shares
CY2016Q1	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	469000	shares
CY2015Q1	regn	Other Collaboration Revenue OtherCollaborationRevenue	123846000	USD
CY2016Q1	regn	Other Collaboration Revenue OtherCollaborationRevenue	179592000	USD
CY2015Q1	regn	Period For Achieving Sales Target For Milestone Payment Rolling Basis PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis	P12M
CY2015Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	162152000	USD
CY2016Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	240867000	USD
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	644112000	USD
CY2016Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	733276000	USD
CY2014Q4	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	7500000	USD
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	140962000	USD
CY2016Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	120595000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1152489000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1450572000	USD
CY2015Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	153152000	USD
CY2016Q1	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	173782000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8572000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4364000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3099526000	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3049651000	USD
CY2015Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-177748000	USD
CY2016Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-136396000	USD
CY2015Q4	us-gaap	Assets Assets	5609132000	USD
CY2016Q1	us-gaap	Assets Assets	5904460000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	2915095000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	3133379000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	868282000	USD
CY2016Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	800175000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14622000	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12216000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2769000	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6531000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	856429000	USD
CY2016Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	794490000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	92000	USD
CY2016Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	689000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	2769000	USD
CY2016Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	6531000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	755080000	USD
CY2016Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	287042000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	2677000	USD
CY2016Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	5842000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	731331000	USD
CY2016Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	151831000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	23749000	USD
CY2016Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	135211000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	600695000	USD
CY2016Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	533795000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	236121000	USD
CY2016Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	244965000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	836816000	USD
CY2016Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	778760000	USD
CY2015Q1	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	2500000.0	USD
CY2016Q1	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	2000000.0	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	648719000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	507907000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	809102000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	604214000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-140812000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-204888000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	71674000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	161528000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	42570000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	78942000	USD
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	586059000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	871541000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	51914000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	73626000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	82015000	USD
CY2016Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	170658000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	461945000	USD
CY2016Q1	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	543689000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16027000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22977000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.74
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.59
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.66
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.45
CY2015Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.725
CY2016Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.498
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	133223000	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	92668000	USD
CY2015Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	169794000	USD
CY2016Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	15649000	USD
CY2015Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2016Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2015Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	91400000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	276523000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	330151000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200502000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	164415000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	30117000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	103431000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	329746000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	397428000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	37256000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	79785000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-7457000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	91205000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5434000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	62263000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-43434000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-39260000	USD
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2512000	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1278000	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	44000	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9313000	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8147000	shares
CY2015Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2016Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	56000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	11197000	USD
CY2016Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	14231000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	238578000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	303294000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	59151000	USD
CY2016Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	85180000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	132068000	USD
CY2016Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	157921000	USD
CY2015Q1	us-gaap	Inventory Write Down InventoryWriteDown	1700000	USD
CY2016Q1	us-gaap	Inventory Write Down InventoryWriteDown	4300000	USD
CY2015Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	180000	USD
CY2016Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2249000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	1954295000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	2139378000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5609132000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5904460000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	811162000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	919724000	USD
CY2015Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	236121000	USD
CY2016Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	244965000	USD
CY2015Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	632162000	USD
CY2016Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	555210000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	90396000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-190543000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-129481000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43685000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-101727000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	29340000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	76021000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	165736000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	76021000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	165792000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7030000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	843000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	283553000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	329308000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	85644000	USD
CY2016Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	102639000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5810000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5791000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4347000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4208000	USD
CY2015Q1	us-gaap	Other Expenses OtherExpenses	7210000	USD
CY2016Q1	us-gaap	Other Expenses OtherExpenses	1406000	USD
CY2015Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	36162000	USD
CY2016Q1	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	45962000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	13563000	USD
CY2016Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	13508000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	115535000	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	120993000	USD
CY2015Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-8808000	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3957000	USD
CY2015Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	27837000	USD
CY2016Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	17381000	USD
CY2015Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	124531000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	242117000	USD
CY2015Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	21192000	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1042000	USD
CY2015Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	95775000	USD
CY2016Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2015Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	114162000	USD
CY2016Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	104094000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	163501000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	115685000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	76273000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	39304000	USD
CY2015Q1	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	6738000	USD
CY2016Q1	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-598000	USD
CY2015Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	80456000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	60409000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1594120000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1666391000	USD
CY2016Q1	us-gaap	Realized Gain Loss On Marketable Securities And Cost Method Investments Excluding Other Than Temporary Impairments And Other Investments RealizedGainLossOnMarketableSecuritiesAndCostMethodInvestmentsExcludingOtherThanTemporaryImpairmentsAndOtherInvestments	0	USD
CY2016Q1	us-gaap	Realized Gain Loss On Marketable Securities Cost Method Investments And Other Investments RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments	0	USD
CY2015Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	16686000	USD
CY2016Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1739000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	343113000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	470112000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	852700000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1018436000	USD
CY2015Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	173356000	USD
CY2016Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	219694000	USD
CY2015Q1	us-gaap	Revenues Revenues	869612000	USD
CY2016Q1	us-gaap	Revenues Revenues	1200849000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	544573000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	784182000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	158991000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	289677000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	103759000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	142250000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	146253	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	16774	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	3654837000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	3765082000	USD
CY2015Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	USD
CY2016Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	144078000	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3642820	shares
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	3659588	shares
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	306069000	USD
CY2016Q1	us-gaap	Treasury Stock Value TreasuryStockValue	307478000	USD
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24781000	USD
CY2015Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	38072000	USD
CY2015Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	55249000	USD
CY2016Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	42465000	USD
CY2015Q1	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	37517000	USD
CY2016Q1	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	57583000	USD
CY2015Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	24226000	USD
CY2016Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	70367000	USD
CY2015Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12292000	shares
CY2016Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9938000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114519000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114228000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102227000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104290000	shares
CY2016Q1	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">. The amendments </font><font style="font-family:inherit;font-size:10pt;color:#333333;">require an entity to recognize all excess tax benefits and tax deficiencies in connection with stock-based compensation as income tax expense or benefit in the income statement. The amendments also require recognition of excess tax benefits regardless of whether the benefit reduces taxes payable in the current period, and excess tax benefits will be classified as an operating activity in the statement of cash flows. The tax effects of exercised or vested awards will be treated as discrete items in the reporting period in which they occur. The amendments are </font><font style="font-family:inherit;font-size:10pt;">effective for annual periods, and interims periods within those annual periods, beginning after December 15, 2016. Early adoption is permitted. The Company is evaluating the impact that this guidance will have on the Company's financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. The new standard requires a lessee to recognize in its balance sheet (for both finance and operating leases) a liability to make lease payments ("lease liability") and a right-of-use asset representing its right to use the underlying asset for the lease term. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company is evaluating the impact that this guidance will have on the Company's financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued Accounting Standards Update 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">. The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Other than an amendment relating to presenting in comprehensive income the portion of the total change in the fair value of a liability resulting from a change in instrument-specific credit risk (if the entity has elected to measure the liability at fair value), early adoption is not permitted. The implementation of the amendments is expected to increase the volatility of an entity's net income; however, the Company is not currently able to estimate the impact of adopting these amendments, as the significance of the impact will depend on the Company's equity investment balance upon adoption. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which will replace existing revenue recognition guidance. The new standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. To achieve that core principle, an entity must identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when (or as) the entity satisfies the performance obligation. In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities. The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. The Company has not yet determined its method of transition and is evaluating the impact that this guidance will have on the Company's financial statements.</font></div></div>
CY2016Q1	us-gaap	Revenue Recognition Revenue Reductions RevenueRecognitionRevenueReductions	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees, and other sales-related deductions. </font></div></div>

Files In Submission

Name	View Source	Status
0001532176-16-000055-index-headers.html	Edgar Link	pending
0001532176-16-000055-index.html	Edgar Link	pending
0001532176-16-000055.txt	Edgar Link	pending
0001532176-16-000055-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-033116x10q.htm	Edgar Link	pending
regn-20160331.xml	Edgar Link	completed
regn-20160331.xsd	Edgar Link	pending
regn-20160331_cal.xml	Edgar Link	unprocessable
regn-20160331_def.xml	Edgar Link	unprocessable
regn-20160331_lab.xml	Edgar Link	unprocessable
regn-20160331_pre.xml	Edgar Link	unprocessable
regn-ex_101x03312016x10q.htm	Edgar Link	pending
regn-ex_102x03312016x10q.htm	Edgar Link	pending
regn-ex_311x03312016x10q.htm	Edgar Link	pending
regn-ex_312x03312016x10q.htm	Edgar Link	pending
regn-ex_32x03312016x10q.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2016 Q1 Form 10-Q Financial Statement

#000153217616000055 Filed on May 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2016 Q1 Form 10-Q Financial Statement

#000153217616000055 Filed on May 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn